ADC Therapeutics SA (ADCT)
- Previous Close
4.9700 - Open
4.9900 - Bid 4.9100 x 800
- Ask 4.9700 x 800
- Day's Range
4.8737 - 5.0000 - 52 Week Range
0.3600 - 6.0400 - Volume
34,460 - Avg. Volume
740,172 - Market Cap (intraday)
406.046M - Beta (5Y Monthly) 1.74
- PE Ratio (TTM)
-- - EPS (TTM)
-2.9400 - Earnings Date May 7, 2024 - May 12, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.20
ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
www.adctherapeutics.comRecent News: ADCT
Performance Overview: ADCT
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ADCT
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ADCT
Valuation Measures
Market Cap
410.17M
Enterprise Value
255.95M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
5.84
Price/Book (mrq)
--
Enterprise Value/Revenue
3.68
Enterprise Value/EBITDA
-1.76
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-24.54%
Return on Equity (ttm)
--
Revenue (ttm)
69.56M
Net Income Avi to Common (ttm)
-240.05M
Diluted EPS (ttm)
-2.9400
Balance Sheet and Cash Flow
Total Cash (mrq)
278.6M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-79.93M